Kornimate/medical-research-clean huggingface dataset:
awareness of osteoporosis in patients with hepatitis b infection

Conditions: Hepatitis B; Osteoporosis; Osteoporosis Risk

Summary: osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density. patients with hepatitis b virus infection are at increased risk for developing osteoporosis. identifying whether patients with hepatitis b virus infection have information and awareness about this disease is crucial. this study is aimed to investigate awareness and knowledge of osteoporosis in patients with hepatitis b virus infection.

osteoporosis is a common disease of bone loss. the reduced bone strength predisposes an increased risk for fractures in older individuals. it can affect people from different ethnicity. many factors increase the risk of osteoporosis, including age, postmenopausal state, glucocorticoid use, low body weight, calcium, vitamin d, immobility, and chronic inflammation. patients with hepatitis b virus infection are at high risk of developing osteoporosis due to chronic inflammation and their medications. patients' knowledge and awareness about osteoporosis are essential for early detection, implementation of lifestyle changes, and treatment compliance. this study aimed to investigate osteoporosis awareness and knowledge about osteoporosis in patients with hepatitis b virus infection.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hepatitis b virus infection * must be between the ages of 18 and 99 * must give consent to participate in the study exclusion criteria: • not giving consent
mechanisms involved in the benefits of an exercise programme in patients with cirrhosis

Conditions: Cirrhosis

Summary: the investigators conducted a pilot study including 17 patients with liver cirrhosis showing that a moderate exercise programme during three months increased thigh circumference,exercise tolerance and quality of life without adverse effects. the present study aim to more accurately evaluate the effect of exercise on muscle mass, effort tolerance and inflammatory response in patients with cirrhosis. this study will include 30 patients with compensated liver cirrhosis that will be randomized into two groups: exercise group and control group. evaluation of muscle mass, effort tolerance, inflammatory response and quality of life will be made at the beginning and at the end of the study.

exercise group: will do a physiotherapist supervised exercise programme 1 hour three times per week during three months and relaxation after exercise. control group: only relaxation 1 hour three times per week during three months. assessment: clinical and laboratory examinations performed at baseline and at the end of the study. the investigators will analyze the changes in muscle mass by anthropometric measurements and advanced techniques (ct scan, densitometry), effort tolerance (stress test), quality of life (sf-36), glutamine synthetase activity in blood, oxidative damage and inflammatory response. the investigators will analyze the survival and complications of cirrhosis during the study and follow-up.

Eligibility criteria:
inclusion criteria: * compensated liver cirrhosis exclusion criteria: * hepatocellular carcinoma * active alcoholism (less than 1 year) * decompensated cirrhosis * variceal bleeding less than 3 months. * contraindication for exercise

Keywords: cirrhosis exercise relaxation muscle mass effort tolerance
novaferon in non-hospitalized adult patients with mild covid-19

Conditions: Covid19

Summary: an adaptive, multicenter, randomized, double-blind, placebo-controlled phase iii study to evaluate the efficacy and safety of aerosolized jh509 vs. placebo in non-hospitalized adult patients with mild covid-19


Eligibility criteria:
inclusion criteria: 1. written informed consent has been obtained from the participants with an age of over 20 years at the time of signing the informed consent. 2. sars-cov-2 infection is diagnosed by rt-pcr within 72 hours before starting drug administration. 3. less than six days from onset of covid-19-related symptoms below to starting the administration of the investigational drug with at least one of the following symptoms observed at the time of enrollment : fever (37.5c or higher), respiratory symptoms (cough, shortness of breath, sore throat, runny nose, etc.), headache, myalgia, malaise, abdominal pain, diarrhea, nausea/vomiting, dysosmia, dysgeusia, or other covid-19 symptoms defined by investigators or coinvestigators investigators. 4. oxygen saturation (spo2) measured by pulse oximeter is more than 95%. 5. require no supplemental oxygen. 6. women (less than 12 months after the last menstrual period) who have a negative pregnancy test (urine hcg qualification) and agree to use highly effective contraceptive methods (taking oral contraceptives or use of condom by male partner) during the study period. investigators or coinvestigators investigators will provide guidance on contraceptive methods. 7. women who are not breast-feeding. exclusion criteria: 1. history of hypersensitivity to interferon or jh509 or any excipients of interferon or jh509. 2. have received antiviral treatments and drugs expected to have antiviral effects (favipiravir, remdesivir, interferon, nafamostat mesilate, and basiliximab/imdevimab, including drugs that are being newly developed and that have been approved) in the past or having had it considered necessary to receive these treatments during the study period. 3. having had it considered necessary to receive treatments, such as drugs containing corticosteroids (excluding topical drugs), antimicrobial agents, and inhalants other than the investigational drug during the study period. 4. taking "shosaikoto," an herbal medicine. 5. neuropsychiatric disorder and autoimmune disorder. 6. ctcae grade 3 or higher liver dysfunction (alt/ast \> 5uln) or renal dysfunction (egfr \< 30 ml/min/1.73 m2). 7. active infections or other medical conditions that contraindicate inhalation therapy. 8. having the complication of malignant tumor or a history of malignant tumor within 1 year before consent acquisition. 9. inappropriate for inclusion in the clinical trial as determined by investigators or coinvestigators investigators.

Keywords: antiviral sars-cov-2 covid19
early diagnosis and timely treatment of cirrhotic patients with minimal hepatic encephalopathy (chess-ncrcid 2106)

Conditions: Hepatic Encephalopathy; Cirrhosis

Summary: hepatic encephalopathy (he) is a common complication of cirrhosis, which seriously damages the life quality of patients. as the disease progresses, 50-80% of patients with cirrhosis develop he. minimal hepatic encephalopathy (mhe) is a manifestation of he, in which the patient usually has no obvious clinical symptoms and can only be detected by neuropsychological testing. early identification and timely treatment are the keys to improve the prognosis of he, and the diagnosis of mhe are the priority in the process of the disease intervention. guidelines in many countries suggest that mhe does not recommend routine treatment. however, patients with cirrhosis usually have complex clinical complications, so whether timely treatment should be taken remains to be explored. the purpose of this study is to investigate the incidence of mhe in cirrhotic patients, and to establish a real-world cohort for further study on drug therapy and efficacy evaluation.

according to the 2017 global burden of disease study, there are 10.6 million patients with decompensated cirrhosis and 112 million patients with compensated cirrhosis worldwide. from 1990 to 2016, the number of patients with cirrhosis and chronic liver disease in china has increased from nearly 7 million (6833 300) to nearly 12 million (11 869 600), and the prevalence of all age groups increased by 44%. hepatic encephalopathy (he) is a common complication of cirrhosis, which seriously damages the life quality of patients. as the disease progresses, 50-80% of patients with cirrhosis develop he. minimal hepatic encephalopathy (mhe) is a manifestation of he, in which the patient usually has no obvious clinical symptoms and can only be detected by neuropsychological testing. early identification and timely treatment are the keys to improve the prognosis of he, and the diagnosis of mhe are the priority in the process of the disease intervention. guidelines in many countries suggest that mhe does not recommend routine treatment. however, patients with cirrhosis usually have complex clinical complications, so whether timely treatment should be taken remains to be explored. the purpose of this study is to investigate the incidence of mhe in cirrhotic patients, and to establish a real-world cohort for further study on drug therapy and efficacy evaluation.

Eligibility criteria:
inclusion criteria: 1. age 18-65 years; 2. confirmed cirrhosis based on clinical or pathological criteria; 3. no history of grade 1-4 hepatic encephalopathy; 4. with written informed consent. exclusion criteria: 1. with other neurological or mental diseases (such as alzheimer's disease, parkinson's disease, etc.); 2. with alcohol or drug addiction and unstable vital signs; 3. with liver cancer or other malignant tumors; 4. fail to comply with psychological tests; 5. incomplete data collection.

Keywords: minimal hepatic encephalopathy cirrhosis psychometric hepatic encephalopathy score
a phase i trial of tecogalan sodium ( ds-4152 ) administered as an infusion weekly x 4

Conditions: Sarcoma, Kaposi; HIV Infections

Summary: to evaluate the safety of different doses and dosing regimens of tecogalan sodium (ds-4152) and to establish the mtd at each of the different dosing schedules.

patients receive intravenous ds-4152 by infusion weekly for 4 weeks, followed by 2 weeks of rest; courses may repeat. patients undergo weekly follow-up. a punch biopsy will be obtained from patients with kaposi's sarcoma.

Eligibility criteria:
inclusion criteria patients must have: * kaposi's sarcoma plus hiv infection or metastatic solid tumor. * life expectancy of at least 12 weeks. * no symptomatic aids-defining opportunistic infection within the past 4 weeks. * recovered from toxicity of any prior anticancer therapy. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * leukemia or lymphoma. * current gastrointestinal bleeding by stool guaiac. * extensive bone metastases or significant radiographic osteoporosis in patients with solid tumors. * active heart disease such as uncontrolled angina, uncompensated congestive heart failure, or dysrhythmias requiring antiarrhythmics. * acute intercurrent infection other than genital herpes. * symptomatic or known central nervous system involvement (including brain metastases) unless stable and off therapy. concurrent medication: excluded: * other anticancer therapy. * other investigational agents. patients with the following prior conditions are excluded: * history of acute or chronic gastrointestinal bleeding or inflammatory bowel disease. * history of myocardial infarction within past 6 months. prior medication: excluded: * anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin c). * investigational agents within the past 4 weeks.

Keywords: neoplasms sarcoma, kaposi acquired immunodeficiency syndrome antineoplastic agents tecogalan
evaluating in cirrhotics with refractory vasoplegia the effect of methylene blue

Conditions: Septic Shock; Vasoplegia; Cirrhosis, Liver; Refractory Shock

Summary: mortality rates associated septic shock remains unacceptably high, around 20-50%, with refractory hypotension in half of these patients. widespread vasodilatation involves the activation of the soluble intracellular enzyme guanylate cyclase (gc) by nitric oxide (no), resulting in the production of cyclic guanosine monophosphate (cgmp). initially discovered as an endothelium-derived relaxing factor in blood vessels, no is made by the enzyme nitric oxide synthase (nos). it has been suggested that the inhibition of no generation might be a treatment option for sepsis and septic shock. methylene blue (mb) is a dye that easily crosses cell membranes, inhibits inos, and is capable of inhibiting the gc enzyme in vascular smooth muscle cells.early use of mb can block the progressive decrease in systemic vascular resistance of patients unresponsive to noradrenaline and mitigate the need for prolonged vasoconstrictor use. the investigators propose to study the effect of methylene blue on cirrhotic adults with sepsis, with refractory vasoplegia unresponsive to maximum doses of noradrenaline and vasopressin.


Eligibility criteria:
inclusion criteria: 1. adult patients (\>18 years ) 2. refractory septic shock (noradrenaline \>0.5mcg/kg/mt ) exclusion criteria: 1. declined consent 2. pregnancy 3. less than 18 years old 4. immunosuppressant patients (e.g. on steroid medication, active anti-cancer chemotherapeutic agent, etc.) 5. glucose-6-phosphate dehydrogenase deficiency 6. medication of serotonin modulator/ssri 7. pre-existing pulmonary hypertension 8. ckd-stage iv/v 9. patients with gi bleed 10. patients on dnr 11. patients declared brain dead

Keywords: methylene blue septic shock vasoplegia cirrhosis
study of the response to irradiation on prostatic explants ex vivo, as a predictive factor of the clinical response to irradiation of prostate cancers

Conditions: Prostate Cancer

Summary: of the 50,000 prostate cancers that occur each year in france, more than half will benefit from curative radiotherapy, alone or in combination with hormone therapy from 6 months to 3 years depending on the stage of the disease. at present, there are few ways to predict the response to this irradiation. evaluating the early response of tumor tissue to irradiation could predict the final response to treatment. it is difficult to offer biopsies during treatment for reasons of patient comfort. this is why this study consists in analysing transcriptomic and protein responses (immunohistochemistry) to irradiation on ex vivo prostate explants. these explants will be irradiated after culture and the transcriptional and immunohistochemical changes analysed before and after irradiation to determine an early tumor tissue response profile to irradiation.


Eligibility criteria:
inclusion criteria: 1. ≥ 18 years old 2. patient with non-operated prostate adenocarcinoma for whom radiotherapy treatment is scheduled 3. signed informed consent 4. no contraindications to biopsy performance: * no anticoagulant treatment in progress * absence of infection during diagnostic biopsies * absence of pain requiring level 2 analgesics during diagnostic biopsies * absence of bleeding complications during diagnostic biopsies * absence of anal stenosis 5. normal coagulation examination : * prothrombin ratio between 80 and 100%. * active cephalin time from 24 to 41 seconds, \> 1.5 times that of the indicator * platelets \> 150,000 g/l * international normalised ratio(inr) = 1 after stopping the anticoagulant 6. no contraindication to mri: * ocular metallic foreign body * pacemaker * old mechanical heart valve * ancient vascular clips on cranial aneurysms exclusion criteria: 1. history of radical prostatectomy. a history of transurethral prostate resection is not a contraindication 2. history of prostate infection 3. hemorrhagic complications in diagnostic biopsies 4. pain requiring level 2 analgesics in diagnostic biopsies 5. anticoagulant treatment in progress (aspirin will be stopped 1 week before biopsies are performed) 6. abnormal coagulation assessment 7. anal stenosis 8. contraindications to radiotherapy: chronic inflammatory bowel disease, scleroderma 9. protected or tutored patient 10. patient whose follow-up at two years is not possible

Keywords: radiotherapy explants transcriptomic immunohistochemistry
the use of microneedles in photodynamic therapy

Conditions: Actinic Keratosis

Summary: the global aim of this study is to investigate how microneedles can facilitate the penetration and efficacy of photodynamic therapy in the treatment of actinic keratoses the specific aims are as follows: 1. investigate whether pretreatment with microneedles enhances penetration of topical aminolevulinic acid (ala) that is marketed as levulan® kerasticks by dusa pharmaceuticals inc. 2. investigate whether pretreatment with microneedles can decrease the required incubation times of the topical ala prior to exposure to blue light photodynamic therapy.


Eligibility criteria:
inclusion criteria: 1. subjects who are 18 and older 2. subjects who have at least 3 actinic keratoses on each side of the forehead 3. subjects who signed an irb approved informed consent exclusion criteria: 1. subjects who smoke 2. subjects who have a photosensitizing condition such as lupus, porphyria, or similar condition. 3. subjects who received a diagnosis of skin cancer on the face in past year 4. subjects who received field treatment for actinic keratoses to the face in the past 60 days

Keywords: actinic keratosis microneedles photodynamic therapy levulan aminolevulinic acid
a placebo controlled, randomized, double blind trial of milnacipran for the treatment of idiopathic neuropathy pain

Conditions: Idiopathic Peripheral Neuropathy

Summary: this is an 11-week randomized, double-blind, placebo-controlled trial of milnacipran 100 mg/d in patients with idiopathic neuropathic pain. milnacipran, a dual norepinephrine and serotonin reuptake inhibitor has been a safe and beneficial treatment for patients with fibromyalgia and may be useful to treat patients with painful peripheral neuropathy. the primary outcome will be assessed by the change in daily averaged weekly 0-10 pain intensity score, from baseline to week 9, by intention to treat analysis. the same analysis will be used on several secondary measures including daily averaged weekly 0-10 pain intensity score the sleep interference scale and the rand-36 quality of life scale.

milnacipran helps serotonin and noradrenaline work more effectively on the central nervous system. serotonin and noradrenaline are molecules made by the brain that affect how your body responds to pain. milnacipran, a dual norepinephrine and serotonin reuptake inhibitor has been a safe and beneficial treatment for patients with fibromyalgia and may be useful to treat patients with painful peripheral neuropathy. many clinical trials for neuropathy pain are done in patients with diabetic neuropathy. idiopathic neuropathy however, is a common cause of neuropathy and accounts for 25% of all neuropathies, and over 50% of small fiber neuropathies. the information in this study will provide information on whether milnacipran also provide benefit as a medication for neuropathic pain.

Eligibility criteria:
inclusion criteria: * male and female patients age 18 to 80 years * patients with signs and symptoms of a peripheral neuropathy, with either abnormal nerve conductions or abnormal epidermal nerve fiber density with neuropathic pain. * pain will have been present for at least 6 months * patients may be on other medications for neuropathic pain (eg, antiepileptic medications, opiates or non steroidal antiinflammatories); however they must be on a stable dose for 4 weeks prior to, with no plan to change during the study * all patients must have had a normal fasting glucose or b12, thyroid stimulating hormone, and serum protein electrophoresis, since the onset of their symptoms. exclusion criteria: * other cause of neuropathy (eg, diabetic neuropathy, toxic neuropathy, hiv neuropathy, celiac neuropathy, inherited neuropathy) * unstable angina * use of another serotonin and norepinephrine reuptake inhibitors (eg, duloxetine, venlafaxine), tricyclic antidepressants, monoamine oxidase inhibitors (maoi) or selective serotonin reuptake inhibitors * myocardial infarction stroke or life threatening arrhythmia within the last 6 months * hiv infection * hepatic or renal failure * pregnancy * narrow angle glaucoma * history of epilepsy or a seizure

Keywords: milnacipran idiopathic peripheral neuropathy diabetic neuropathy neuropathic pain
homeopathy for prevention of atrial fibrillation after aortocoronary bypass surgery

Conditions: Atrial Fibrillation

Summary: after heart surgery, about 30% of patients suffer from atrial fibrillation. patients are randomized into two groups receiving either potentized strychnos nux vomica or placebo under double blind conditions. postoperatively, ecgs are done to monitor cardiac rhythm.

preoperatively, patients receive potentized nux vomica or placebo sublingually. then, patients are observed regarding atrial fibrillation postsurgical. the difference between the group of patients with and without nux vomica is recorded.

Eligibility criteria:
inclusion criteria: * patients before elective heart valve - or aortocoronary by pass surgery with heart-lung-machine. exclusion criteria: * pregnant patients * patients with preoperative atrial fibrillation and/or hyperthyreosis

Keywords: nux vomica homeopathy heart lung machine heart surgery postoperatively studied
targeted forceps biopsy for colorectal tumors

Conditions: Colorectal Neoplasms

Summary: this study evaluates whether targeted forceps biopsy with careful tumor surface evaluation can improve diagnostic accuracy of colorectal tumors larger than 2 cm during colonoscopy.


Eligibility criteria:
inclusion criteria: * patients with colorectal neoplasms of the size larger than 2 cm exclusion criteria: * patients who deny the participation in the study

Keywords: forceps biopsy colorectal tumors
temperature of extremities and necrotizing enterocolitis

Conditions: Neutral Temperature; Bloody Stool; Necrotizing Enterocolitis

Summary: bloody stool and necrotizing enterocolitis(nec) is two main focus in non-neonatal intensive care unit ward and usually lead to longed duration of hospitalization. neutral temperature is a environmental temperature where the infant's body temperature is normal under resting state, and the changes of body temperature and skin temperature are less than 0.2-0.3 centigrade. according the definition, a suggested temperature range is set. for example, if an infant's body weight is more than 2500 gram, the initial set of environmental temperature is 31.3 centigrade with a range of 29.8-32.8 centigrade. low environmental temperature is a risk factor for bloody stool and nec. therefore, how to set the optimal environmental temperature is a challenge.

after birth, newborns must adapt to their relatively cold environment by the metabolic production of heat because they are not able to generate an adequate shivering response. under the condition, environment temperature should be given to protect an infant from cold stress and cold injury, even nec. therefore, the setting of the optimal environment temperature is a key focus in neonatal ward. here, the investigators suggest a hypothesis that environment temperature should be set to keep warmth of extremities temperature and infant's body temperature is between 36.7-37.3 centigrade. in the present study, the investigators will test the hypothesis.

Eligibility criteria:
inclusion criteria: * body weight \>2500 grams and/or gestational age \>35 weeks * an infant is diagnosed with hyperbilirubinemia and/or pneumonia without need for oxygen inhalation exclusion criteria: * congenital deformities * refusal of parents' consent